Bariatric surgery and pharmacological interventions, such as GLP-1 receptor agonists, effectively reduce body weight and improve obesity-related comorbidities but frequently result in substantial loss of lean body mass, particularly in the early stages of treatment. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.